Iloperidone: Efficacy Review for the Acute Treatment of Schizophrenia in Adults
نویسندگان
چکیده
Iloperidone is one of the newest second generation antipsychotic medications approved in the United States for the acute treatment of schizophrenia in adults. Iloperidone binds tightly to serotonin-2A (5HT2A) and dopamine-2 (D2) receptors with very little affinity to histamine-1 (H1) and muscarinic-1,2 (M1–2) receptors. The efficacy of iloperidone for the treatment of schizophrenia has been established in three 6 week trials, one 4 week trial, and three 52-week follow-up studies. Iloperidone is generally well tolerated. The most common adverse effects observed in clinical studies of iloperidone are dizziness, weight gain, sedation, tachycardia, and orthostatic hypotension. This medication may serve as an additional treatment option for patients with schizophrenia.
منابع مشابه
New atypical antipsychotics for schizophrenia: iloperidone
The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics. Iloperidone is a new dopamine type 2/serotonin type 2A (D(2)/5-HT(2A)) antagonist structurally related to risperidone, expected to give better efficacy with less extrapyramidal symptoms t...
متن کاملLong-term efficacy and safety of iloperidone: an update
Schizophrenia is a devastating neuropsychiatric disease with a worldwide prevalence of approximately 0.5%-1%. Since many patients do not achieve adequate symptom relief from available agents, alternate pharmacotherapeutic approaches are needed. In this context, iloperidone was recently approved by the US Food and Drug Administration for the treatment of schizophrenia. This paper first reviews i...
متن کاملIloperidone for the treatment of schizophrenia: an updated clinical review.
Iloperidone is a second-generation "atypical" antipsychotic whose primary mechanism of action is within the subclass of combined D2/5HT2A antagonism. Iloperidone was approved by the FDA in May 2009 for the treatment of schizophrenia. This review is a comprehensive synthesis of the history and clinical trials data leading up to approval, and evaluates iloperidone within the clinical context of h...
متن کاملIloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy
INTRODUCTION Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies. AIM To revi...
متن کاملEffect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.
AIMS Presence of the null FS63TER allele of the rs1800169 polymorphism in the gene encoding the ciliary neurotrophic factor (CNTF) may increase the risk of schizophrenia. This study prospectively evaluated the CNTF rs1800169 genotype (G/G vs non-G/G) effects on response to iloperidone. PATIENTS & METHODS Iloperidone 24 mg/day was evaluated in a study of patients with schizophrenia. Efficacy m...
متن کامل